Clinical trials in Montpellier – page 83

1 094 clinical trials in Montpellier, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Montpellier at a glance

1 094

clinical trials

Research sites4

Quick filters

1 094 trials in Montpellier

Open in trial search

Colitis ulcerative

Not recruiting

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational

France

Participants:18–64 years · 65+ years
Substances:(Phosphonooxy)Methyln-[(S)-[1-(Bicyclo[1.1.1]Pentan1-Yl)-1H-1,2,3-Triazol-4-Yl](2-Methyl-1-Oxo-1,2-Dihydroisoquinolin-5-Yl)Methyl]-N-{8-Chloro-3-Cyano-4-[(2,2-Dimethylpropyl)Amino]Quinolin-6-Yl]Carbamate
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Malignant melanoma

Not recruiting

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Apalutamide
Sponsor:Janssen Cilag International

Contact Research Centre

Chronic kidney disease

Not recruiting

Study on the Effect of Dapagliflozin in Reducing Proteinuria in Patients with Chronic Kidney Disease After Kidney Transplant

Registered drugNo placebo

Study on the Effect of Dapagliflozin in Reducing Proteinuria in Patients with Chronic Kidney Disease After Kidney Transplant

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Binge eating

Not recruiting

Study on BP1.4979 for Treating Binge Eating Disorder in Women with Moderate to Severe Symptoms

Investigational

Study on BP1.4979 for Treating Binge Eating Disorder in Women with Moderate to Severe Symptoms

Investigational

France

Participants:18–64 years · 65+ years
Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
Sponsor:Bioprojet Pharma

Contact Research Centre

Juvenile spondyloarthritis+2

Not recruiting

Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis

Registered drugNo placebo

Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis

Registered drugNo placebo

France

Participants:0–17 years
Substances:Adalimumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Kidney transplant rejection

Not recruiting

Study on Tegoprubart for Preventing Kidney Transplant Rejection in Patients

Registered drugNo placebo

Study on Tegoprubart for Preventing Kidney Transplant Rejection in Patients

Registered drugNo placebo

France

Participants:18–64 years
Substances:At-1501
Sponsor:Eledon Pharmaceuticals Inc.

Contact Research Centre

HIV infection

Not recruiting

Study Comparing Integrase Inhibitor (Bictegravir) and Boosted Protease Inhibitor (Darunavir) Treatments for Patients with Advanced HIV Infection

Registered drugNo placebo

Study Comparing Integrase Inhibitor (Bictegravir) and Boosted Protease Inhibitor (Darunavir) Treatments for Patients with Advanced HIV Infection

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bictegravir
Sponsor:NEAT ID Foundation

Contact Research Centre

Crohn's disease

Not recruiting

Study on Managing Moderate Postoperative Recurrence in Crohn's Disease with Infliximab for Patients After Ileocolonic Surgery

Registered drugNo placebo

Study on Managing Moderate Postoperative Recurrence in Crohn's Disease with Infliximab for Patients After Ileocolonic Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Montpellier

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, bladder cancer, and mantle cell lymphoma. Studies evaluate combination therapies and novel treatment approaches for improved patient outcomes.

Advanced HNSCC Treatment Combinations
Non-muscle Invasive Bladder Cancer Therapy
Gastric Cancer Targeted Treatments

Research includes evaluation of immunotherapy combinations and targeted molecular approaches.

02 Autoimmune Conditions

Studies examining innovative treatments for Crohn's disease, multiple sclerosis, and systemic sclerosis. Research focuses on novel therapeutic approaches and treatment optimization.

Fecal Microbiota Transplantation Studies
MS Treatment De-escalation Strategies
Advanced Autoimmune Therapies

Trials aim to improve disease management and patient quality of life.

03 Rare Diseases

Investigating treatments for achondroplasia, pyruvate dehydrogenase deficiency, and thyroid eye disease. Focus on developing targeted therapies for these uncommon conditions.

Growth Disorders in Children
Metabolic Disease Management
Innovative Therapeutic Approaches

Research aims to address unmet medical needs in rare disease populations.

04 Preventive Medicine

Clinical trials evaluating vaccines for cytomegalovirus, yellow fever, and HPV prevention. Studies focus on immunization effectiveness and safety profiles.

Vaccine Development Programs
Infection Prevention Strategies
Population Health Protection

Research emphasizes disease prevention and public health improvement.

Back to France All countries